| Gary E Oppenheim, MD | |
|
550 17th Ave, Suite 450, Seattle, WA 98122-5788 | |
| (206) 861-8550 | |
| (206) 861-8551 |
| Full Name | Gary E Oppenheim |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 43 Years |
| Location | 550 17th Ave, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083639249 | NPI | - | NPPES |
| 0194895 | Other | WA | L & I |
| 8119877 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD00027825 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Medical Center / Cherry Hill | Seattle, WA | Hospital |
| Swedish Medical Center | Seattle, WA | Hospital |
| Swedish Edmonds Hospital | Edmonds, WA | Hospital |
| Swedish Issaquah | Issaquah, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Swedish Health Services | 7517870645 | 74 |
News Archive
Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.
A team of researchers at Goethe University in Germany has observed the RNA folding structures of the SARS-CoV-2 genome that aids the infection process.
Preliminary research presented today at APHA's 2017 Annual Meeting and Expo examined the trend in hospitalizations from opioid poisonings in West Virginia, a state heavily impacted by the current opioid overdose crisis.
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.
Taking advantage of powerful advances in CRISPR gene editing, scientists at the University of California San Diego have set their sights on one of society's most formidable threats to human health.
› Verified 7 days ago
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659328177 PECOS PAC ID: 7517870645 Enrollment ID: O20031106000104 |
News Archive
Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.
A team of researchers at Goethe University in Germany has observed the RNA folding structures of the SARS-CoV-2 genome that aids the infection process.
Preliminary research presented today at APHA's 2017 Annual Meeting and Expo examined the trend in hospitalizations from opioid poisonings in West Virginia, a state heavily impacted by the current opioid overdose crisis.
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.
Taking advantage of powerful advances in CRISPR gene editing, scientists at the University of California San Diego have set their sights on one of society's most formidable threats to human health.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gary E Oppenheim, MD Po Box 25608, Salt Lake City, UT 84125-0608 Ph: (206) 320-4476 | Gary E Oppenheim, MD 550 17th Ave, Suite 450, Seattle, WA 98122-5788 Ph: (206) 861-8550 |
News Archive
Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.
A team of researchers at Goethe University in Germany has observed the RNA folding structures of the SARS-CoV-2 genome that aids the infection process.
Preliminary research presented today at APHA's 2017 Annual Meeting and Expo examined the trend in hospitalizations from opioid poisonings in West Virginia, a state heavily impacted by the current opioid overdose crisis.
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.
Taking advantage of powerful advances in CRISPR gene editing, scientists at the University of California San Diego have set their sights on one of society's most formidable threats to human health.
› Verified 7 days ago
Sandhya Ramanathan Panch, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |